Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968634 | 0.90 | RET (0.36) | RETSYKTNIKIGF1RROCK2 | |
| SCHEMBL22966858 | 0.87 | CACNA2D1 (0.43) | SYKTNIKMAOBROCK2KDR | |
| SCHEMBL24610278 | 0.85 | RET (0.48) | RETSYKTNIKMAOBIGF1R | |
| SCHEMBL22966949 | 0.81 | MAOB (0.46) | RETSYKTNIKMAOBROCK2 | |
| SCHEMBL21217622 | 0.79 | ROCK2 (0.53) | MAOBROCK2 | |
| SCHEMBL24094235 | 0.77 | NPC1 (0.44) | RETSYKTNIKROCK2EGFR | |
| SCHEMBL22967054 | 0.76 | ROCK2 (0.53) | ROCK2EGFRALDH1A1MAPTHPGD | |
| SCHEMBL21217772 | 0.75 | TNIK (0.61) | RETSYKTNIKROCK2KDM4E | |
| SCHEMBL24094106 | 0.75 | ROCK2 (0.47) | RETSYKTNIKMAOBROCK2 | |
| SCHEMBL24610311 | 0.75 | AGPAT2 (0.42) | RETSYKTNIKIGF1RROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | RET 1721/4885SYK 1214/4885TNIK 249/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | RET 1738/4885SYK 1081/4885TNIK 251/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | RET 1721/4885SYK 1214/4885TNIK 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.